Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Calleja, Miguel Angel
- dc.contributor.author Albanell Mestres, Joan
- dc.contributor.author Aranda, Enrique
- dc.contributor.author García-Foncillas, Jesús
- dc.contributor.author Feliu, Anna
- dc.contributor.author Rivera, Fernando
- dc.contributor.author Oyagüez, Itziar
- dc.contributor.author Salinas-Ortega, Laura
- dc.contributor.author Soto Alvarez, Javier
- dc.date.accessioned 2022-07-26T06:43:10Z
- dc.date.available 2022-07-26T06:43:10Z
- dc.date.issued 2021
- dc.description.abstract Objective: to assess the economic impact of introducing biosimilars of bevacizumab for the management of cancer patients receiving systemic bevacizumab in the National Health System (SNHS) of Spain. Methods: a 3-year budget impact analysis model was adapted to estimate the cost of introducing biosimilars of bevacizumab in the SNHS for the adult population who were candidates to receive treatment with bevacizumab. Values for the estimation of the population were obtained from the literature and were validated by an expert panel. In this analysis only pharmaceutical costs (€, year 2021) obtained from official databases were considered. A sensitivity analysis was performed to examine the robustness of the model. Results: the introduction of bevacizumab biosimilars would generate an annual cost saving of €11 558 268 (-5.1%) for the first year with a penetration share of biosimilars from 30.0%, €29 126 373 (-8.5%) for the second year with a share of 50.0% and €52 361 778 (-13.6%) for the third year with a share of 80.0%. The total pharmaceutical costs of the scenario without biosimilars are €227 033 352 for the first year, €342 663 209 for the second year and €385 013 076 for the third year. In contrast, the pharmaceutical costs of the scenario with bevacizumab biosimilars are €215 475 084, €313 536 836 and €332 651 297 for years 1, 2 and 3, respectively. Conclusions: the introduction of biosimilars in the Spanish Health System would generate saving costs in the pharmacological budget to boost biological drugs from the first year.
- dc.format.mimetype application/pdf
- dc.identifier.citation Calleja MA, Albanell J, Aranda E, García-Foncillas J, Feliu A, Rivera F, Oyagüez I, Salinas-Ortega L, Soto Alvarez J. Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain. Eur J Hosp Pharm. 2023 Mar;30(e1):e40-e47. DOI: 10.1136/ejhpharm-2021-002955
- dc.identifier.doi http://dx.doi.org/10.1136/ejhpharm-2021-002955
- dc.identifier.issn 2047-9956
- dc.identifier.uri http://hdl.handle.net/10230/53807
- dc.language.iso eng
- dc.publisher BMJ Publishing Group
- dc.relation.ispartof Eur J Hosp Pharm. 2023 Mar;30(e1):e40-e47
- dc.rights This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is noncommercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by-nc/4.0/
- dc.subject.keyword Antineoplastic agents
- dc.subject.keyword Economics
- dc.subject.keyword Health care economics and organizations
- dc.subject.keyword Medical oncology
- dc.subject.keyword Pharmaceutical
- dc.subject.keyword Public health
- dc.title Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion